Legend Biotech targets 2026 adjusted profitability as it revises Q4 gross margin outlook to high 50% range

Seeking Alpha · November 10, 2026, 21:32 UTC

Tickers: $LEGN

Topics: financial outlook gross margin guidance profitability targets

Read the full article at Seeking Alpha

Part of the story Legend Biotech Reports Q3 2026 Profitability Driven by CARVYKTI Global Expansion (2 articles)

More World news

Mercantile Bank Announces New Full-Service Banking Center in Holland, Michigan PR Newswire · November 12, 2026, 19:28 UTC
Broadwind Reports 48% Revenue Growth and Record Industrial Solutions Backlog in Q3 2026 Motley Fool · November 12, 2026, 19:25 UTC
MediWound Reports Q3 2026 Financial Results Amid Clinical Trial Expansion Motley Fool · November 12, 2026, 19:25 UTC
Twist Bioscience Reports Q4 2026 Revenue Growth and First Positive Adjusted EBITDA Motley Fool · November 12, 2026, 19:25 UTC
Chicago Atlantic BDC Reports Q3 2026 Growth in Net Investment Income and Record Portfolio Value Motley Fool · November 12, 2026, 19:25 UTC
Google Integrates Gemini 4 Hydrogen Model into Search to Enhance Complex Query Handling TechCrunch · November 12, 2026, 19:27 UTC
General Motors Partners with NorthStar Clean Energy for Large-Scale Solar Project in Michigan Seeking Alpha · November 12, 2026, 19:24 UTC
CNBC Select Names Accredited Debt Relief Best for Debt Resources PR Newswire · November 12, 2026, 19:25 UTC
CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Tetra Tech Forecasts FY 2027 Revenue Between $4.425B and $4.625B Amid Backlog Growth Seeking Alpha · November 12, 2026, 19:20 UTC